GlassScriptPhysician profile
Natalie Len
NPI 1013629047
$14,688.80
in general payments reported to CMS, 2019-2025
31 companies · $4,481 in 2025
The $4,481 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $5,864 · 2024: $4,344 · 2025: $4,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,681.28 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,232.71 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,429.45 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,003.03 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $991.32 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $773.52 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neuronetics, INC. | $754.84 | 2023-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $736.32 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $583.40 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $582.57 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $571.34 | 2023-2025 | Auvelity |
| Noven Therapeutics, LLC | $477.96 | 2023-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $467.85 | 2024-2025 | Rexulti |
| Corium, LLC | $413.90 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $412.53 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $389.11 | 2023-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $388.91 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $285.13 | 2023-2025 | Loreev Xr, Gralise |
| Neos Therapeutics, LP | $266.49 | 2023-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $187.28 | 2023-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $140.38 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $135.08 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $104.39 | 2025 | Jornay Pm |
| Validus Pharmaceuticals LLC | $104.17 | 2023-2024 | Equetro |
| Sage Therapeutics, LLC | $62.76 | 2023-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $50.33 | 2025 | Cobenfy |
| Indivior INC. | $42.10 | 2023 | Perseris |
| Owp Pharmaceuticals, INC. | $24.90 | 2025 | Subvenite |
| Noven Pharmaceuticals, INC. | $23.14 | 2024 | Xelstrym |
| Harmony Biosciences LLC | $22.24 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.02 | 2024 | Relexxii |
| Avion Pharmaceuticals | $14.63 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Len listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.